Agenus Inc. stock is up 6.37% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 24 March’s closed higher than February. In the last 2 Unusual Options Trades, there were 2 CALLs.
Agenus Inc. discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!